ProCE Banner Activity

Expert Selections From ASH 2020: Lymphomas/CLL

Conference Coverage
Clinical Thought
In this commentary, Jeremy S. Abramson, MD, MMSc, discusses the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Released: March 11, 2021

Expiration: March 10, 2022

Share

Faculty

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, Allogene, AstraZeneca, BeiGene, Bluebird, C4 Therapeutics, Celgene, EMD Serono, Genentech, Incyte, Karyopharm, Kite, Morphosys, and Novartis.